This vaccine uses dental floss instead of needles

The innovative technique, developed by a team led by Harvinder Singh Gill, the Ronald B. and Cynthia J. McNeill Term Professor in Nanomedicine at North Carolina State University, and detailed in the journal Nature Biomedical Engineering, represents a significant stride towards enhancing mucosal immunity, particularly against respiratory pathogens like influenza and COVID-19. This groundbreaking approach leverages the unique permeability of the junctional epithelium—a thin layer of tissue located in the deepest part of the gum pocket—to stimulate a robust antibody response not only in the bloodstream but critically, also on mucosal surfaces such as the lining of the nose and lungs.

The Quest for Mucosal Immunity: A New Frontier in Vaccine Delivery

For decades, the vast majority of vaccines have been administered via intramuscular injection. While highly effective at stimulating systemic immunity—producing antibodies that circulate throughout the bloodstream—these traditional methods often fall short in generating a strong localized immune response on mucosal surfaces. These surfaces, including the respiratory tract, gastrointestinal tract, and urogenital tract, serve as the primary entry points for a wide array of pathogens. Consequently, a vaccine that can effectively fortify these mucosal "gateways" offers an additional, crucial line of defense, potentially preventing infection at its very outset rather than merely mitigating disease severity after a pathogen has gained entry.

"Mucosal surfaces are important, because they are a source of entry for pathogens, such as influenza and COVID," explains Professor Gill, corresponding author of the pivotal paper. He further elaborates on the limitation of traditional injections: "If a vaccine is given by injection, antibodies are primarily produced in the bloodstream throughout the body, and relatively few antibodies are produced on mucosal surfaces. But we know that when a vaccine is given via the mucosal surface, antibodies are stimulated not only in the bloodstream, but also on mucosal surfaces. This improves the body’s ability to prevent infection, because there is an additional line of antibody defense before a pathogen enters the body."

The concept of mucosal vaccination is not entirely new; oral vaccines (like those for polio and rotavirus) and intranasal vaccines (like some flu vaccines) exist. However, these methods often face challenges related to vaccine degradation in the harsh environment of the digestive system, or the robust barrier properties of the nasal epithelium that prevent efficient vaccine uptake. The search for an alternative, effective, and patient-friendly mucosal delivery system has thus been a long-standing goal in vaccinology.

Unlocking the Junctional Epithelium: Nature’s Permeable Gateway

The key to this new floss-based method lies in a specific anatomical feature: the junctional epithelium. Epithelial tissues generally form robust barriers across the body, designed to protect underlying tissues from external threats ranging from viruses and bacteria to environmental pollutants. This protective function, while vital, also presents a significant hurdle for vaccine delivery. The lining of the lungs, stomach, and intestines, for instance, are formidable barriers.

However, the junctional epithelium stands apart. It is a unique, thin layer of tissue situated in the deepest part of the gingival sulcus, the shallow crevice or pocket between the tooth and the surrounding gum. Unlike most other epithelial tissues, the junctional epithelium lacks the typical robust barrier features. This inherent permeability is biologically advantageous in its natural role: it allows immune cells to readily migrate into the gingival sulcus to combat bacteria that naturally colonize this area, contributing to the immune components found in saliva and the fluid between teeth and gums.

"Because the junctional epithelium is more permeable than other epithelial tissues—and is a mucosal layer—it presents a unique opportunity for introducing vaccines to the body in a way that will stimulate enhanced antibody production across the body’s mucosal layers," Gill states, highlighting the physiological rationale behind targeting this specific site. This anatomical peculiarity offers a window of opportunity, a ‘soft spot’ in the body’s defenses that can be strategically utilized for therapeutic benefit.

The Experimental Journey: From Lab Mice to Human Feasibility

The research team embarked on a systematic investigation to validate the junctional epithelium as a viable vaccine delivery route. The initial phase of their work involved animal models, specifically lab mice, to assess the immune response generated by this novel method.

Phase 1: Animal Model Efficacy Testing
The researchers applied a peptide flu vaccine to unwaxed dental floss. They then meticulously flossed the teeth of lab mice, ensuring the vaccine-coated floss made contact with the junctional epithelium. To benchmark the effectiveness of this new method, they compared the antibody production in these mice against control groups that received the vaccine through two other established mucosal delivery routes:

1. Nasal Epithelium: Vaccine delivered intranasally, a common route for some flu vaccines.
2. Sublingual Mucosal Tissue: Vaccine placed under the tongue, representing another oral cavity delivery approach.

The results were compelling. Rohan Ingrole, the first author of the paper and a former Ph.D. student under Gill at Texas Tech University, reported: "We found that applying vaccine via the junctional epithelium produces far superior antibody response on mucosal surfaces than the current gold standard for vaccinating via the oral cavity, which involves placing vaccine under the tongue." This finding underscores the significant advantage of the floss-based method over sublingual administration, a route that often struggles with consistent absorption and immune stimulation.

Furthermore, the flossing technique demonstrated comparable protection against the flu virus as vaccination via the nasal epithelium. This is particularly noteworthy given the inherent challenges associated with intranasal delivery. "This is extremely promising, because most vaccine formulations cannot be given via the nasal epithelium—the barrier features in that mucosal surface prevent efficient uptake of the vaccine," Gill explains. He also points out a critical safety concern with intranasal delivery: "Intranasal delivery also has the potential to cause the vaccine to reach the brain, which can pose safety concerns. However, vaccination via the junctional epithelium offers no such risk." For their comparison, the team specifically chose one of the few vaccine formulations known to work effectively for nasal delivery, ensuring a rigorous "best-case scenario" comparison.

Phase 2: Broad Spectrum Applicability
Beyond the initial peptide flu vaccine, the researchers expanded their investigation to determine if the junctional epithelium delivery method was versatile enough for other prominent classes of vaccines. They tested:

• Proteins: A common vaccine type, often requiring adjuvants to boost immune response.
• Inactivated Viruses: Whole viruses that have been killed, used in many established vaccines.
• mRNA: The cutting-edge technology behind many recent COVID-19 vaccines.

In all three cases, the epithelial junction delivery technique consistently produced robust antibody responses, both in the bloodstream (systemic immunity) and crucially, across various mucosal surfaces. This broad applicability suggests the method’s potential across a wide spectrum of infectious diseases and vaccine platforms, making it a highly adaptable innovation.

An interesting practical finding from the animal model studies was that consuming food and water immediately after flossing with the vaccine did not diminish the immune response. This suggests a high degree of stability and rapid uptake, which would simplify patient instructions and improve compliance in a real-world scenario.

Bridging the Gap: From Lab to Practicality

While unwaxed dental floss proved effective for precise application in lab mice, the researchers acknowledged the logistical challenges of asking individuals to manually coat floss and apply it effectively. This led to the next phase: evaluating a more practical delivery mechanism for human use.

Phase 3: Human Feasibility with Floss Picks
The team turned to a readily available and user-friendly alternative: the floss pick. A floss pick consists of a piece of floss stretched between two prongs, attached to a handle, making it much easier to manipulate and target specific areas of the mouth.

To assess the feasibility of delivering a substance to the junctional epithelium using a floss pick, the researchers conducted a small human study. They coated the floss on floss picks with a fluorescent food dye. Twenty-seven study participants were then instructed on the concept of applying a substance via floss and asked to attempt depositing the food dye into their epithelial junction using the floss pick.

The results were encouraging. "We found that approximately 60% of the dye was deposited in the gum pocket, which suggests that floss picks may be a practical vaccine delivery method to the epithelial junction," Ingrole reported. While 100% deposition is ideal, 60% is a substantial proportion, indicating that a significant amount of vaccine could reliably reach the target tissue, potentially enough to elicit a protective immune response. This finding is a critical step towards demonstrating the translational potential of the method for human application.

Advantages Beyond Immunity: Patient Experience and Public Health

The implications of this floss-based vaccine delivery extend beyond the enhanced immune response. It addresses several significant challenges in global vaccination efforts:

1. Needle-Free Administration: A major psychological barrier for many individuals, particularly children and those with needle phobia (trypanophobia), is the fear of injections. A floss-based method entirely eliminates needles, potentially increasing vaccine acceptance and compliance across demographics. Professor Gill highlights this: "For example, it would be easy to administer, and it addresses concerns many people have about being vaccinated with needles." This could be a game-changer for public health campaigns, especially in regions with high vaccine hesitancy due to fear of injections.

2. Ease of Administration and Accessibility: Compared to complex administration procedures, using a floss pick is a familiar action for many. This simplicity could facilitate self-administration or administration by non-medical personnel, reducing the burden on healthcare infrastructure and expanding access to vaccination, especially in remote or underserved areas.

3. Cost-Effectiveness: The researchers anticipate the technique to be comparable in price to other vaccine delivery methods. The materials involved—floss picks and vaccine formulations—are generally inexpensive, and the simplified administration could reduce costs associated with trained personnel and specialized equipment. "And we think this technique should be comparable in price to other vaccine delivery techniques," Gill states.

4. Enhanced Mucosal Protection: As detailed, the primary scientific advantage is the superior stimulation of mucosal antibodies, offering a frontline defense against pathogens that enter via respiratory or other mucosal routes. This is particularly relevant in an era of respiratory pandemics, where sterilizing immunity at the point of entry could significantly curb transmission.

Challenges and the Road Ahead

Despite its promise, the floss-based vaccination method is still in its early stages, and several questions remain before it can be considered for widespread clinical use.

1. Applicability to All Age Groups: The method relies on the presence of teeth and gums. "This technique would not work on infants and toddlers who do not yet have teeth," notes Gill, indicating a limitation for the youngest populations who are often vulnerable to infectious diseases. Alternative delivery methods would still be necessary for this age group.

2. Impact of Oral Health: The integrity of the junctional epithelium is crucial for this method. "In addition, we would need to know more about how or whether this approach would work for people who have gum disease or other oral infections," Gill cautions. Periodontal disease, which affects a significant portion of the adult population globally, could potentially alter the permeability or immune response of the junctional epithelium, necessitating further research.

3. Regulatory Pathway and Clinical Trials: The journey from animal models and human feasibility studies to approved clinical use is long and rigorous. The next critical step involves human clinical trials to assess safety, optimal dosing, and efficacy in larger and more diverse populations. "We’re optimistic about that work and—depending on our findings—may then move toward clinical trials," Gill confirms. These trials would systematically evaluate immune responses, protection against infection, and any potential side effects.

4. Vaccine Formulation and Stability: While the study showed broad applicability across vaccine types, specific formulations might need optimization to ensure stability on floss and efficient delivery and uptake.

A Collaborative Effort and Future Outlook

The research paper, "Floss-based vaccination targets the gingival sulcus for mucosal and systemic immunization," published in Nature Biomedical Engineering, represents a collaborative effort. Co-authors include Akhilesh Kumar Shakya, Chang Hyun Lee, and Lazar Nesovic of Texas Tech University; Gaurav Joshi of Texas Tech and NC State; and Richard Compans of Emory University.

The study received vital financial support from the National Institutes of Health (NIH) under grants R01AI137846 and R01DE033759, and from funds provided by the Whitacre Endowed Chair in Science and Engineering at Texas Tech University. The intellectual property generated from this pioneering work is also being protected, with Gill, Ingrole, and Shakya listed as co-inventors on a patent related to targeting the junctional epithelium for vaccination. This patent underscores the commercial and public health potential seen in this innovative approach.

If successful in future clinical trials, floss-based vaccination could represent a paradigm shift in how vaccines are delivered, offering a safe, effective, needle-free, and potentially self-administrable option that significantly enhances mucosal immunity. This could have profound implications for global health, improving vaccine equity, boosting public acceptance, and strengthening our collective defense against current and future infectious disease threats. The dental floss, a ubiquitous tool for oral hygiene, may soon add "vaccine delivery device" to its repertoire, silently revolutionizing the landscape of preventive medicine.